Only one week left to enter the Patient Partnership Index 2021
7th May 2021
With the entry deadline of Friday 14
th May fast approaching, there’s just one week left to tell us about your work with patient groups and be part of the Patient Partnership Index 2021. If your company isn’t already taking part, there’s still time to enter and help set the standard for patient partnerships.
As the UK’s leading initiative to showcase communications and advocacy partnerships between biopharmaceutical companies and patient groups, the Index is an exciting opportunity for companies of all sizes to not only share examples of their work, but to define best practice for the entire industry.
Raising the bar
Across Europe, as well as the rest of the world, the COVID-19 pandemic has shown the vital importance of working together to tackle obstacles. Wherever you may be, the vision for healthcare is the same – to help people live the healthiest, best lives they can.
I’ve spent around half of my career working in the voluntary sector and the other half with industry. Over this time, I’ve watched partnerships between the two shift from transactional and often narrow in scope, to strategic and focussed on getting the best outcomes for patients as quickly as possible.
PharmaTimes -
May 2021
This month we celebrate women from various factions of healthcare who are all striving to achieve better outcomes for patients in their vastly different roles, showcasing their careers, interests, achievements and thoughts on the future. Turn to page 17 to meet some of the brightest stars across pharma, communications and healthcare.
With patient outcomes also clearly centre stage, on page 30 Craig Adkins says now is the time to level up care for patients with irritable bowel disorder (IBD), a condition for which there is an urgent need for a national disease strategy and the application of a standard of care across the country, while on page 34, looking at 15 years of biosimilars in Europe, Rebecca Guntern highlights that the opportunity to leverage biosimilars ‘as an obvious and sustainable way to increase patient access to medicines has never been closer’.